Skip to content

Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts

IL-4 and IFN-γ As Immunologic Predictors of Response to HPV Immunotherapy in Warts

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05100043
Enrollment
80
Registered
2021-10-29
Start date
2020-01-03
Completion date
2021-03-02
Last updated
2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wart, Genital, Warts Hand

Brief summary

In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation

Detailed description

40 Patients and 40 controls are enrolled in the study. Participants suffer from chronic recurrent cutaneous and genital warts. Blood samples were withdrawn then whole blood cultures are prepared. Cultures are stimulated with bivalent HPVvaccine. IL-4 and IFN-γ measurement in culture supernatants by ELISA. IL-4 and IFN-γ are investigated to predict the therapeutic response to bivalent HPV vaccine immunotherapy in warts.

Interventions

BIOLOGICALIL-4 and IFN-γ measurements

Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
36 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with recurrent and recalcitrant cutaneous and anogenital warts.

Exclusion criteria

* History of allergy to the HPV vaccine * Active viral, fungal, or bacterial infections * Immunosuppressive diseases or drugs. * Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders, diabetes, meningitis or convulsions * Skin allergies * Pregnancy and lactation * Earlier wart treatment at least one month before enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Change of IFN-γ and IL-4 levels48 hoursQuantitative measurement of IFN-γ and IL-4 in culture supernatants

Secondary

MeasureTime frameDescription
Change in the size of warts6 monthsClinical observation and photographing of wart size

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026